Navigation Links
Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Date:10/20/2011

LA JOLLA, Calif., Oct. 20, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and collaborators at NYU Langone Medical Center and Wake Forest Baptist Medical Center today announced the publication of new pre-clinical research findings in the journal Nature (Rayner et al., Nature, October 20, 2011). The new data show the first demonstration of marked increases in high density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and suppression of plasma triglyceride levels in non-human primates through inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with proprietary chemically modified anti-miR oligonucleotides. A webinar to discuss the new data will be hosted by Regulus and features Kathryn Moore, Ph.D., associate professor in the Department of Medicine at NYU Langone Medical Center and Regulus scientists (11:00am EDT, October 26, 2011).

"In addition to atherosclerotic plaque regression and enhanced reverse cholesterol transport that we previously observed in rodents with our collaborators at NYU Langone Medical Center, anti-miR-33 treatment is now shown to increase HDL cholesterol and lower triglycerides in non-human primates," said Hubert C. Chen, M.D., Vice President of Translational Medicine at Regulus. "These combined data sets provide strong evidence that an anti-miR-33 therapeutic approach can offer multiple mechanisms to benefit patients with atherosclerosis. Anti-miR-33a/b is one of several microRNA therapeutic programs we are advancing toward clinical development."

Dr. Moore said, "The current study is the first to demonstrate in non-human primates that inhibition of miR-33a/b can both increase circulating levels of HDL-C and suppress plasma triglyceride levels. This study highligh
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
3. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
4. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
5. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
6. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
7. Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
8. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
9. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
10. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
11. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... WEST PALM BEACH, Fla. , July 11, 2014 ... wide variety of high-quality peptides that are used solely ... online. To honor two successful years in business, Maxim ... Performance LLC, has just launched a new and updated ... addition, the research blog section has been updated with ...
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... MRIGlobal, an internationally recognized research and development organization ... has appointed Richard A. Winegar, Ph.D., to Principal Advisor ... Dr. Winegar is a recognized expert in ... genetic toxicology.  As Principal Advisor for Science, he will ...
... July 11, 2011 Avisena, one of the nation,s ... for physician practices, today announced the extension of a ... facility will be used to accelerate the Company,s strategic ... and marketing. "Square 1 believes in supporting ...
... Pharma, Inc. is pleased to announce that it has ... its lead drug for the treatment of stroke and ... A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single ... of Oral and Intravenous Administration of Methamphetamine Hydrochloride in ...
Cached Biology Technology:MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science 2Avisena Closes $2.5 Million of Debt Capital By Square 1 Bank 2Sinapis Pharma Completes Phase I Trial 2
(Date:7/14/2014)... oxygen control insect body size? What influence does genetics have ... of Current Opinion in Insect Science launched ... Current Opinion in Insect Science is the latest ... review journal that aims to provide specialists with a unique ... published in the field of insect science. First articles published ...
(Date:7/14/2014)... with roots in the local environment manage much better ... from foreign environments. , A world without bees ... Denmark alone an additional 600 million to 1 billion ... done by bees making honey and pollinating a wide ... , Unfortunately, bees all over the world are under ...
(Date:7/14/2014)... genes that improved the harvesting of sunlight, a new ... genomes reveals. The findings could help current efforts to ... a ,genetic snapshot, of maize as it existed 10 ... of its genome a ,whole genome duplication, event. ... ,copied, genes to cope with the pressures of domestication, ...
Breaking Biology News(10 mins):Best for bees to be stay-at-homes 2A-maize-ing double life of a genome 2
... gases and increase production at the same time has been ... Industries' (DPI) Wollongbar Agricultural Institute. , Trials of agrichar - ... and the environment - have doubled and, in one case, ... tonnes per hectare. , Agrichar is a black ...
... tiger now occupies a mere 7 percent of its historic ... has declined by 41 percent over the past decade, according ... BioScience. Growing trade in folk medicines made from tiger parts ... believed to be the chief reason for the losses. The ...
... long been clear that smoking causes cancer, but new research ... who smokes. , Canadian researchers have demonstrated in ... of sperm cells, alterations that could potentially be inherited by ... June 1 issue of Cancer Research, a journal of the ...
Cached Biology News:Soils offer new hope as carbon sink 2Soils offer new hope as carbon sink 3Threats to wild tigers growing 2Cigarette smoke alters DNA in sperm, genetic damage could pass to offspring 2
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... AS-2055 and AS-2057 are fully automatic sample ... possible level of precision. Sampling flexibility is ... (microplate) for,laboratory automation and combinatorial chemistry. Also ... or the standard rack for 50 2,ml ...
...
... Covance's BCIP/NBT Chromogen system ... Tetrazolium] chromogen in a single ... reacts in the presence of ... purple staining with minimal background ...
Biology Products: